The purpose of this study is to evaluate efficacy of tyrosine as a treatment for methamphetamine dependence in an outpatient treatment setting providing group psychosocial interventions. Examine effect of tyrosine on abstinence, retention in treatment, and craving."

Condition	Treatment or Intervention	Phase
Amphetamine-Related Disorders	Behavior: Tyrosine	Phase II

Further Study Details: 

Expected Total Enrollment:  89

Evaluate efficacy of tyrosine as a treatment for methamphetamine dependence in an outpatient treatment setting providing group psychosocial interventions. Examine effect of tyrosine on abstinence, retention in treatment and craving.

Ages Eligible for Study:  18 Years   -   65 Years,  Genders Eligible for Study:  Both

Criteria

Inclusion Criteria:

18-65 years of age. Able to provide informed consent. Desire to reduce/eliminate methamphetamine use. Used within the past two weeks. Meet DSM criteria for methamphetamine dependence.

Exclusion Criteria:

No dependence (within the past 12 months) for other durgs except nicotine. No history or family history of tyrosine intolerance.

California
      Haight Ashbury Free Clinics, San Francisco,  California,  94117,  United States

Study chairs or principal investigators

Gantt Galloway, Pharm.D.,  Principal Investigator,  Haight Ashbury Free Clinics   

Study ID Numbers:  NIDA-10739-1; R01-10739-1
Record last reviewed:  April 1997
Last Updated:  November 18, 2004
Record first received:  September 20, 1999
ClinicalTrials.gov Identifier:  NCT00000322
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08